Subscribe
shutterstock_1569668848_sundry_photography
Sundry Photography / Shutterstock.com
16 January 2020AmericasSarah Morgan

Gilead hit with antitrust suit over HIV drugs

Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
US govt seeks new trial in Gilead HIV drug patent case
18 May 2023   The government lost its high stakes and unusual royalties dispute with the big pharma firm | New status report claims that the court should have allowed the jury to take four inter partes petitions into account.
Big Pharma
Gilead sues US govt for breach of contract over antiviral patents
29 April 2020   Gilead has escalated its dispute with the US federal government by filing a new lawsuit accusing it of improperly filing for patents covering HIV drug Truvada.
Americas
Gilead to face HIV antitrust claims
5 March 2020   Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
US govt seeks new trial in Gilead HIV drug patent case
18 May 2023   The government lost its high stakes and unusual royalties dispute with the big pharma firm | New status report claims that the court should have allowed the jury to take four inter partes petitions into account.
Big Pharma
Gilead sues US govt for breach of contract over antiviral patents
29 April 2020   Gilead has escalated its dispute with the US federal government by filing a new lawsuit accusing it of improperly filing for patents covering HIV drug Truvada.
Americas
Gilead to face HIV antitrust claims
5 March 2020   Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.

More on this story

Big Pharma
US govt seeks new trial in Gilead HIV drug patent case
18 May 2023   The government lost its high stakes and unusual royalties dispute with the big pharma firm | New status report claims that the court should have allowed the jury to take four inter partes petitions into account.
Big Pharma
Gilead sues US govt for breach of contract over antiviral patents
29 April 2020   Gilead has escalated its dispute with the US federal government by filing a new lawsuit accusing it of improperly filing for patents covering HIV drug Truvada.
Americas
Gilead to face HIV antitrust claims
5 March 2020   Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.

More features

Sanofi unit loses genetic disorder patent at EPO after trio of challenges
INTA confirms London as host city for Annual Meeting 2026
INTA unveils key principles on AI and IP rights at Annual Meeting
Illumina takes aim at rival in gene sequencing spat
Novartis tops Big Pharma in global trademark portfolios
PierFerd hires partner with medtech expertise
NanoString to pay 10x Genomics $68m in global settlement
Federal Circuit revives CRISPR feud citing PTAB errors